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Empyema is a severe complication of different diseases and traumas. Management of this complication is
difﬁcult and should comprise general and local procedures. The general procedure is mainly based on
administering wide-spectrum antibiotics. Local management depends on general condition, but in all
cases the essential procedure is inserting a drain into the pleural cavity and evacuation the pus.
Sometimes pus is very thick and its evacuation and re-expansion of the lung is rather impossible. In these
patients surgical procedures are required. The use of intrapleural enzymes to aid drainage was ﬁrst
described in 1949 by Tillett and Sherry using a mixture of streptokinase and streptococcal DNase
(deoxyribonuclease).1 In recent years puriﬁed streptokinase has come into widespread use, but recent
studies suggest that it has no effect on pus viscosity. DNase reduces pus viscosity and may be more useful
in treatment.2 We report a case of intrapleural administration of Pulmozyme (alfa dornase e deoxyri-
bonuclease (HOFFMANN-LA ROCHE AG) in dosage 22,5 mg with a good effect caused by changes in pus
viscosity.
 2011 Elsevier Ltd. All rights reserved.A 33 year old male was admitted to the Pneumonology Depart-
ment because of chest pain on the right side, high temperature over
39 C and weight lose about 5 kg which had been observed for 3
weeks. Clinical examination and chest x-ray revealed an pleural
empyema. Peripheral blood examination was done. There were:
20,9 K/ml leucocytes, 4,32 K/ml erythrocytes, 12,4 g/dl haemoglobin,
37,2% haematocrit, 1,1 mmol/l creatinine, 357,1 mg/l CRP protein. The
patient was treated with intravenous broad spectrum antibiotic.
Thoracentesis was done but no ﬂuid was obtained. The patient
was relocated to the Wroclaw Thoracic Surgery Centre, where the
chest tube was inserted into the pleural cavity. The pleural suction
was maintained three days. Suction at 20 cm H2O was applied.
During the ﬁrst three days only a small amount of pus from pleural
cavity was removed because of high pus density. In the ﬁrst day the
amount of pleural ﬂuid was 300ml, in the second only 30 ml, in the
third 20 ml. In the subsequent two days Pulmozyme was admi-
nistered directly into the pleural cavity through the drain. Total
amount of the administered Pulmozyme was 5 mg 2,5 mg of dor-
nase alfa and 50 ml of normal saline were instilled into the pleural
cavity daily for 2 consecutive days. The tube was clamped for 4 h
after instillation of this agent. During this period patient changedgy, Third Faculty of Medicine,
, Czech Republic. Tel.: þ420
rved.the position (lateral, supine, face down position). On ﬁrst day
900 ml of thin pus was drained, on second day a further 300 ml of
drainagewas obtained with considerable improvement in the x-ray
and the patient’s clinical status. His appetite improved and
temperature decreased. The chest drain was removed on day 10th.
The ﬁrst chest x-ray was performed before treatment and the
last one after removing the drain. After discharge from the hospital
patient was controlled in the hospital outpatient clinic. The x-ray
done after 1 month was better than showed on the fourth picture.
The diaphragm was only slightly elevated and costo-phrenic angle
was shaded Fig. 1.
1. Measurement of viscosity
To measure drainability a 2 ml medical syringe ﬁtted with
1,240 (18G11/2 “) needle was used. Measurement of viscosity
before instillation the dornase alfa was 56 drops/min. After instil-
lation the ﬁrst dose of dornase alfa there was 210 drops/min and
after instillation the second dose there was 225 drops/min.
2. Discussion
Successful treatment of pleural empyema depends on adequate
drainage of pleural cavity. There are two factors which prevent
successful drainage by intercostals tube: loculation of the ﬂuid and
increasing viscosity, and adherence of the pus to the pleural
Fig. 1. (A) Chest x-ray performed before treatment. (B) Chest x-ray performed after inserting drain. (C) Chest x-ray performed after introducing two doses of Pulmozyme. (D) Chest
x-ray performed after removing drain.
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visceral pleura. There are a lot of studies which suggest to use
intrapleural ﬁbrinolytic therapy especially streptokinase and
urokinase in treatment of multiloculated pleural empyemas with
good success rate. Some authors suggest that intrapleural instilla-
tion of ﬁbrinolytic agents appears to be an effective and less inva-
sive alternative to surgical treatment.3e6 Results of some controlled
studies of using puriﬁed streptokinase are divergent.7,8 Simpson et
all suggest that puriﬁed streptokinase was less effective than the
older preparation which contains a small proportion of strepto-
coccal DNase.2 Subsequent studies showed that streptokinase alone
has no effect on pus viscosity but that the inclusion of either
streptococcal or human recombinant DNase reduced signiﬁcantly
viscosity.2 Similar results were obtained in an animal model using
Varidase (the combination of streptokinase and streptodornase).9
Human recombinant DNase seems to be extremely safe and
effective when it is administred by nebulisation in the treatment of
cystic ﬁbrosis.10 The experience with ﬁbrinolytic agents, also with
DNase suggests little absorption of enzymes from the pleural cavity
when used to treat empyema.
Measurement of pleural ﬂuid viscosity using a simple count of
drop rate from the syringe could be useful parameter in evaluation
of treatment’s efﬁcacy.
3. Conclusion
Pulmozyme may be used in some patients with pleural
empyema with good results.Conﬂict of interest statement
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